
Claims

1. A compound having a structure of Formula (III):



(III)

wherein:

L^1 is ~~a bond, C_{1-6}alkylene, or~~ C_{0-3}alkylene---C_{0-2}alkylene, wherein --- indicates a double bond, a triple bond, or a fused cyclopropyl, and when --- is a double bond, it is subsituted with 0-2 C_{1-3}alkyl;

B is C_{0-3}alkylene-X;

X is an aromatic or nonaromatic C_{4-10}carbocycle, or an aromatic or nonaromatic 4-10 membered heterocycle having 1-3 ring heteroatoms selected from N, O, and S, and X is substituted with 0-3 G;

each G independently is selected from the group consisting of halo, OH, =O, CN, NO_2, $N(R^N)_2$, $N(R^N)C(O)C_{1-3}$alkyl, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, $C(O)C_{1-3}$alkyl, $S(O_2)$-Z, C(O)-Z, $C(O)N(R^N)_2$, silyl ether, and $[O]_{0-1}$-C_{0-3}alkylene-Z;

each R^N independently is H or C_{1-4}alkyl;

Z is aromatic or nonaromatic C_{3-10}carbocycle, or aromatic or nonaromatic 4-10 membered heterocycle having 1-3 heteroatoms selected from the group consisting of N, O, and S;

Z is optionally substituted with 1-3 E;

each E independently is selected from C_{1-3}alkyl, C_{1-3}alkoxy, =O, C_{1-3}haloalkoxy, CN, and halo;

R^2 is H or C_{1-3}alkyl;

L^2 is C_{0-3}alkylene;

m is 0 to 2; and

each R^4 independently is C_{1-3}alkyl, C_{2-3}alkynyl, C_{1-3}haloalkyl, C_{1-3}alkoxy, halo, or NHC_{1-3}alkylene-aryl;

or a pharmaceutically acceptable salt thereof.

2. ~~The compound or salt of claim 1, wherein L^1 is a bond.~~

~~3. The compound or salt of claim 1, wherein L^1 is C_{1-6}alkylene.~~


~~4. The compound or salt of claim 3, wherein L^1 is CH_2, CH_2CH_2, $C(CH_3)_2$, $C(CH_3)_2CH_2$, or $C(CH_3)_2CH_2CH_2$.~~

~~5. The compound or salt of claim 1, wherein L^1 is~~ 


~~.~~

~~6.~~2. The compound or salt of claim 1~~5~~, wherein L^1 is 

.

~~7.~~3. The compound or salt of claim 1~~5~~, wherein L^1 is 


.

~~8.~~4. The compound or salt of claim 1~~5~~, wherein L^1 is 
.

~~9.~~5. The compound or salt of any one of claims 1-4~~5-8~~, wherein --- indicates a double bond.

~~10.~~6. The compound or salt of claim 5~~9~~, wherein the double bond is ~~further~~ substituted with 1 or 2 C_{1-3}alkyl.

~~11.~~7. The compound or salt of any one of claims 1-4~~5-8~~, wherein --- indicates a triple bond.

~~12.~~8. The compound or salt of any one of claims 1-4~~5-8~~, wherein --- indicates a fused cyclopropyl, e.g.,  .

~~13.~~9. The compound or salt of any one of claims 1-8~~1-12~~, wherein B is C_{1-3}alkylene-X.

~~14.~~10. The compound or salt of any one of claims 1-8~~1-12~~, wherein B is X.

~~15.~~11. The compound or salt of any one of claims 1-10~~1-14~~, wherein X is pyrrolidinyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, phenyl, piperidinyl, pyridinyl, piperazinyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, quinolinyl, morpholinyl, pyrrolidonyl, pyrimidinyl, pyridazinyl, indenyl, dihydroindenyl, dihydrobenzofuranyl, chromanyl, isochromanyl, dihydroisoquinolinyl, or indolyl.

~~16. The compound or salt of any one of claims 1-15,~~
~~wherein~~

~~X is substituted with 1-3 G;~~

~~each G independently is selected from the group consisting of halo, OH, =O, CN, NO_2, $N(R^N)_2$, $N(R^N)C(O)C_{1-3}$alkyl, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, $C(O)C_{1-3}$alkyl, $S(O_2)$-Z, C(O)-Z, $C(O)N(R^N)_2$, silyl ether, and $[O]_{0-1}$-C_{0-3}alkylene-Z;~~

~~each R^N independently is H or C_{1-4}alkyl;~~

~~Z is aromatic or nonaromatic C_{3-10}carbocycle, or aromatic or nonaromatic 4-10 membered heterocycle having 1-3 heteroatoms selected from the group consisting of N, O, and~~


~~S;~~

~~Z is optionally substituted with 1-3 E; and,~~

~~each E independently is selected from C_{1-3}alkyl, C_{1-3}alkoxy, =O, C_{1-3}haloalkoxy, CN, and halo.~~

~~17. The compound or salt of claim 1,~~

~~wherein~~

~~L^1-B is selected from the group consisting of~~ 

~~X is aromatic or nonaromatic C_{4-7} carbocycle, or an aromatic or nonaromatic 4-9 membered heterocycle having 1 ring heteroatom;~~

~~X is optionally substituted with 1-3 G;~~



~~each G independently is selected from the group consisting of halo, OH, =O, CN, NO_2, $N(R^N)_2$, $N(R^N)C(O)C_{1-3}$alkyl, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, $C(O)C_{1-3}$alkyl, $S(O_2)$ Z, C(O) Z, $C(O)N(R^N)_2$, silyl ether, and $[O]_{0-1}$-C_{0-3}alkylene-Z;~~


~~each R^N independently is H or C_{1-4}alkyl;~~


~~Z is aromatic or nonaromatic C_{3-10}carbocycle, or aromatic or nonaromatic 4-10 membered heterocycle having 1-3 heteroatoms selected from the group consisting of N, O, and S;~~


~~Z is optionally substituted with 1-3 E; and,~~


~~each E independently is selected from C_{1-3}alkyl, C_{1-3}alkoxy, =O, C_{1-3}haloalkoxy, CN, and halo.~~


~~18.~~12. The compound or salt of claim ~~17~~, wherein L^1-B is selected from the group consisting of: , ,


G
N
(G)0-2
N
(G)0-3
N
(G)0-3
N
(G)0-3
O
(G)0-3
O
(G)0-3
O
(G)0-3
O
(G)0-3
, and
O
(G)0-3
O
(G)0-3
NH
(G)0-3
N
G
(G)0-2
(E)0-3
1-4
O
(E)0-3
1-4
O
(E)0-3
1-4
N
(E)0-3
N
(E)0-3
N
N
(E)0-3
N
(E)0-3
N
(G)0-2
1-4
O
O
N
(E)0-3
1-4
(G)0-2
N
(E)0-3
1-4
N
(E)0-3
1-4
N
(E)0-3
1-4
N
(E)0-3
O
1-4




, 



, 


, 


~~, and~~





.


~~19.~~13. The compound or salt of claim 12~~17 or 18~~, wherein L^1-B is selected from the group consisting of: , 


, 


, 


, 








, 


, 


, 


, 

, 



, 



, 







and , ~~, and~~ .


~~20.~~14. The compound or salt of claim 1, wherein L^1-B is selected from the group consisting of:~~.~~ , 

























, , 














,








,

,

,

,

,

,

,

,

,

,

,

, and

.

~~21.~~15. The compound or salt of any one of claims 1-14~~20~~, wherein R^2 is H.

~~22.~~16. The compound or salt of any one of claims 1-14~~20~~, wherein R^2 is $C_{1\text{-}3}$alkyl.

~~23.~~17. The compound or salt of claim 16~~22~~, wherein R^2 is methyl.

~~24.~~18. The compound or salt of any one of claims 1-17~~23~~, wherein L^2 is C_0alkylene.

~~25.~~19. The compound or salt of any one of claims 1-17~~23~~, wherein L^2 is C_1alkylene.

~~26.~~20. The compound or salt of any one of claims 1-17~~23~~, wherein L^2 is C_2alkylene.

~~27.~~21. The compound or salt of any one of claims 1-17~~23~~, wherein L^2 is C_3alkylene.

~~28.~~22. The compound or salt of any one of claims 1-21~~27~~, wherein m is 0.

~~29.~~23. The compound or salt of any one of claims 1-21~~27~~, wherein m is 1 or 2.

~~30.~~24. The compound or salt of claim 23~~29~~, wherein R^4 is $C_{1\text{-}3}$alkyl.

~~31.~~25. The compound or salt of claim 24~~30~~, wherein R^4 is methyl or ethyl.

~~32.~~26. The compound or salt of claim 23~~29~~, wherein R^4 is halo.

~~33.~~27. The compound or salt of claim 26~~32~~, wherein R^4 is F.

~~34.~~28. The compound or salt of claim 26~~32~~, wherein R^4 is Cl.

~~35.~~29. The compound or salt of claim 23~~29~~, wherein R^4 is $C_{2\text{-}3}$alkynyl.

~~36.~~30. The compound or salt of claim 29~~35~~, wherein R^4 is C_2alkynyl.

~~37.~~31. The compound or salt of claim 23~~29~~, wherein R^4 is $C_{1\text{-}3}$haloalkyl.

~~38.~~32. The compound or salt of claim 31~~37~~, wherein R^4 is CF_3.

~~39.~~33. The compound or salt of claim 23~~29~~, wherein R^4 is $C_{1\text{-}3}$alkoxy.


~~40.~~34. The compound or salt of claim 33~~39~~, wherein R^4 is methoxy.

~~41.~~35. The compound or salt of claim 23~~29~~, wherein R^4 is $NHC_{1\text{-}3}$alkylene-aryl.

~~42.~~36. The compound or salt of claim 35~~41~~, wherein R^4 is NH-CH_2-phenyl.


~~43.~~37. The compound or salt of claim 23~~29~~, wherein m is 2, and one R^4 is halo, and the other R^4 is halo or methyl.


~~44.~~38. The compound or salt of any one of claims 1 to 17~~23~~, having the structure of Formula (IIIA):




(IIIA).


~~45. The compound or salt of claim 44, wherein L^1-B is selected from the group consisting of:~~



































~~46.~~39. The compound or salt of claim 38~~44~~, wherein L^1-B is selected from the group consisting of:






,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

and

.


40. The compound or salt of claim 1, wherein the compound or salt is selected from the group consisting of:

,

,

,

, and

.

41. A compound having a structure of Formula (III):



(III)

wherein:

L^1 is a bond;

B is X;

X is pyrrolidinyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, piperidinyl, pyridinyl, piperazinyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, quinolinyl, morpholinyl, pyrrolidonyl, pyrimidinyl, pyridazinyl, indenyl, dihydroindenyl, dihydrobenzofuranyl, chromanyl, isochromanyl, dihydroisoquinolinyl, or indolyl, and X is substituted with 0-3 G;

each G independently is selected from the group consisting of halo, OH, =O, CN, NO_2, $N(R^N)_2$, $N(R^N)C(O)C_{1-3}$alkyl, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3} haloalkyl, C_{1-3} haloalkoxy, $C(O)C_{1-3}$alkyl, $S(O_2)$-Z, C(O)-Z, $C(O)N(R^N)_2$, silyl ether, and $[O]_{0-1}$-C_{0-3}alkylene-Z;

each R^N independently is H or C_{1-4}alkyl;

Z is aromatic or nonaromatic C_{3-10}carbocycle, or aromatic or nonaromatic 4-10 membered heterocycle having 1-3 heteroatoms selected from the group consisting of N, O, and S;

Z is optionally substituted with 1-3 E;

each E independently is selected from C_{1-3}alkyl, C_{1-3}alkoxy, =O, C_{1-3}haloalkoxy, CN, and halo;

R^2 is H or C_{1-3}alkyl;

L^2 is C_{0-3}alkylene;


m is 0 to 2; and


each R^4 independently is C_{1-3}alkyl, C_{2-3}alkynyl, C_{1-3}haloalkyl, C_{1-3}alkoxy, halo, or NHC_{1-3}alkylene-aryl;

or a pharmaceutically acceptable salt thereof;

wherein the compound or salt thereof is not N-[4-[(3-methyl-1-piperidinyl)methyl]2-thiazolyl)-1-(4-pyridinylmethyl)-1H-pyrrole-2-carboxamide.


42. The compound or salt of claim 41, wherein L^1-B is selected from the group consisting of:






, and .

43. The compound or salt of claim 42, wherein L^1-B is selected from the group consisting of:





, and





.

44. The compound or salt of claim 41, wherein L^1-B is selected from the group consisting of:









, and .

45. The compound or salt of any one of claims 41-44, wherein R^2 is H.

46. The compound or salt of any one of claims 41-44, wherein R^2 is C_{1-3}alkyl.

47. The compound or salt of claim 46, wherein R^2 is methyl.

48. The compound or salt of any one of claims 41-47, wherein L^2 is C_0alkylene.

49. The compound or salt of any one of claims 41-47, wherein L^2 is C_1alkylene.

50. The compound or salt of any one of claims 41-47, wherein L^2 is C_2alkylene.

51. The compound or salt of any one of claims 41-47, wherein L^2 is C_3alkylene.

52. The compound or salt of any one of claims 41-51, wherein m is 0.

53. The compound or salt of any one of claims 41-51, wherein m is 1 or 2.

54. The compound or salt of claim 53, wherein R^4 is C_{1-3}alkyl.

55. The compound or salt of claim 54, wherein R^4 is methyl or ethyl.

56. The compound or salt of claim 53, wherein R^4 is halo.

57. The compound or salt of claim 56, wherein R^4 is F.

58. The compound or salt of claim 56, wherein R^4 is Cl.

59. The compound or salt of claim 53, wherein R^4 is C_{2-3}alkynyl.

60. The compound or salt of claim 59, wherein R^4 is C_2alkynyl.

61. The compound or salt of claim 53, wherein R^4 is C_{1-3}haloalkyl.

62. The compound or salt of claim 61, wherein R^4 is CF_3.

63. The compound or salt of claim 53, wherein R^4 is C_{1-3}alkoxy.


64. The compound or salt of claim 63, wherein R^4 is methoxy.

65. The compound or salt of claim 53, wherein R^4 is NHC_{1-3}alkylene-aryl.

66. The compound or salt of claim 65, wherein R^4 is NH-CH_2-phenyl.


67. The compound or salt of claim 53, wherein m is 2, and one R^4 is halo, and the other R^4 is halo or methyl.


68. The compound or salt of any one of claims 41 to 67, having the structure of Formula (IIIA):







(IIIA).

69. The compound or salt of claim 68, wherein L^1-B is selected from the group consisting of:










, and



.


~~47.~~70. The compound or salt of claim 41, wherein the compound or salt is selected from the group consisting of:


,










, ,















, and .







48.71. A compound listed in Table A, or a pharmaceutically salt thereof.







Table A







No.	Structure
~~A1~~	
~~A2~~	
~~A3~~	
~~A4~~	
~~A5~~	
~~A6~~	
~~A7~~	







~~A8~~	
~~A9~~	
~~A10~~	
~~A11~~	
A12	
~~A13~~	







~~A14~~	
~~A15~~	
~~A16~~	
~~A17~~	
~~A18~~	
~~A19~~	







~~A20~~	
~~A21~~	
~~A22~~	
~~A23~~	
~~A24~~	
~~A25~~	







~~A26~~	
~~A27~~	
~~A28~~	
~~A29~~	
~~A30~~	
~~A31~~	






~~A32~~	
A33	
~~A34~~	
~~A35~~	
~~A36~~	
~~A37~~	







~~A38~~	
~~A39~~	
~~A40~~	
~~A41~~	
~~A42~~	
~~A43~~	







~~A44~~	
~~A45~~	
~~A46~~	
~~A47~~	
A48	
~~A49~~	







~~A50~~	
~~A51~~	
~~A52~~	
~~A53~~	
~~A54~~	
~~A55~~	







~~A56~~	
~~A57~~	
~~A58~~	
~~A59~~	
~~A60~~	
~~A61~~	







~~A62~~	
~~A63~~	
~~A64~~	
~~A65~~	
~~A66~~	







~~A67~~	
~~A68~~	
~~A69~~	
~~A70~~	
~~A71~~	
~~A72~~	







~~A73~~	
~~A74~~	
~~A75~~	
~~A76~~	
~~A77~~	
~~A78~~	







~~A79~~	
~~A80~~	
~~A81~~	
~~A82~~	
~~A83~~	
~~A84~~	







~~A85~~	
~~A86~~	
~~A87~~	
~~A88~~	
~~A89~~	
~~A90~~	







~~A91~~	
~~A92~~	
~~A93~~	
~~A94~~	
~~A95~~	
~~A96~~	






~~A97~~	
~~A98~~	
~~A99~~	
~~A100~~	
~~A101~~	
~~A102~~	






~~A103~~	
~~A104~~	
~~A105~~	
~~A106~~	
~~A107~~	
~~A108~~	







~~A109~~	
~~A110~~	
~~A111~~	
~~A112~~	
~~A113~~	
~~A114~~	







~~A115~~	
~~A116~~	
~~A117~~	
~~A118~~	
~~A119~~	
~~A120~~	







~~A121~~	
~~A122~~	
~~A123~~	
~~A124~~	
~~A125~~	
~~A126~~	








~~A127~~	
~~A128~~	
~~A129~~	
~~A130~~	
~~A131~~	








A132	
A133	
A134	
A135	
A136	








A137	
A138	
A139	
A140	
A141	
A142	








A143	
A144	
A145	
A146	
A147	
A148	







A149	
A150	
A151	
A152	
A153	
A154	







A155	
A156	
A157	
A158	
A159	
A160	
A161	







A162	
A163	
A164	
A165	
A166	
~~**A167**~~	
~~**A168**~~	







~~**A169**~~	
~~**A170**~~	
~~**A171**~~	
~~**A172**~~	
~~**A173**~~	
~~**A174**~~	
~~**A175**~~	







~~A176~~	
~~A177~~	
~~A178~~	
~~A179~~	
~~A180~~	
~~A181~~	
~~A182~~	







~~A183~~	
~~A184~~	
~~A185~~	
~~A186~~	
~~A187~~	
~~A188~~	







~~A189~~	
~~A190~~	
~~A191~~	
~~A192~~	
~~A193~~	
A194	







~~A195~~	
~~A196~~	
~~A197~~	
~~A198~~	
~~A199~~	
A200	






~~A201~~	
~~A202~~	
~~A203~~	
~~A204~~	
~~A205~~	
~~A206~~	






~~A207~~	
~~A208~~	
A209	
~~A210~~	
~~A211~~	
~~A212~~	







~~A213~~	
~~A214~~	
A215	
~~A216~~	
A217	
A218	







A219	
A220	
~~A221~~	
A222	
A223	
A224	







~~A225~~	
~~A226~~	
A227	
~~A228~~	
A229	
A230	







A231	
A232	
A233	
A234	
A235	








A236	
A237	
~~A238~~	
A239	
A240	







A241	
A242	
~~A243~~	
A244	
A245	
A246	








A247	
A248	
A249	
~~A250~~	
A251	
A252	








A253	
A254	
A255	
~~A256~~	
~~A257~~	
A258	








A259	
~~A260~~	
A261	
~~A262~~	
~~A263~~	
A264	







A265	
A266	
A267	
A268	
A269	
A270	
A271	









A272	
A273	
A274	
A275	
A276	
A277	








A278	
A279	
~~**A280**~~	
A281	
A282	
A283	
A284	







A285	
A286	
A287	
A288	
A289	
A290	
A291	







A292	
A293	
A294	
A295	
A296	
A297	
A298	







A299	
A300	
A301	
A302	
A303	
A304	







A305	
A306	
A307	
~~A308~~	
A309	
A310	
A311	
A312	






A313	
A314	
~~A315~~	
~~A316~~	
A317	
A318	
A319	







A320	
A321	
A322	
A323	
A324	
A325	







A326	
A327	
A328	
A329	
A330	
A331	







A332	
A333	
A334	
A335	
~~**A336**~~	
A337	






A338	
A339	
~~A340~~	
A341	
A342	
A343	






A344	
A345	
A346	
A347	
~~A348~~	







A349	
A350	
A351	
A352	
A353	
A354	






A355	
A356	
A357	
A358	
A359	
~~A360~~	







A361	
A362	
A363	
A364	
A356	
A366	






~~**A367**~~	
A368	
~~**A369**~~	
A370	
A371	






A372	
A373	
A374	
~~A375~~	
A376	

A377	
A378	
A379	
A380	
A381	
A382	

A383	
A384	
A385	
A386	
A387	

A388	
A389	
A390	
A391	
A392	
A393	

A394	
A395	
A396	
A397	
A398	

A399	
A400	
A401	
A402	
A403	

~~49.~~72. The compound or salt of any one of claims 1-71~~48~~ for use in inhibiting protein secretion, wherein the protein is selected from PD-1, TNFα, HER3, IL2, and combination thereof.

~~50. The compound or salt for use of claim 49, wherein the protein is at least one of PD-1, PD-L1, TIM-1, LAG-3, CTLA4, BTLA, OX-40, B7H1, B7H4, CD137, CD47, CD96, CD73, CD40, VISTA, TIGIT, LAIR1, CD160, 2B4, TGFRβ and combinations thereof.~~

~~51.~~73. Use of the compound or salt of any one of claims 1-71~~48~~ in the manufacture of a medicament for the treatment of inflammation, or a disease selected from a group comprising cancer, autoimmune disease, immune-related disease, neurodegenerative disease and inflammatory disease.